Kalaris Therapeutics (KLRS) Competitors $2.51 +0.05 (+2.03%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock KLRS vs. CCCC, TVGN, SLS, ENTA, LFVN, CYBN, ACTU, NKTX, SLN, and NVCTShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include C4 Therapeutics (CCCC), Tevogen Bio (TVGN), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Silence Therapeutics (SLN), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors C4 Therapeutics Tevogen Bio SELLAS Life Sciences Group Enanta Pharmaceuticals Lifevantage Cybin Actuate Therapeutics Nkarta Silence Therapeutics Nuvectis Pharma C4 Therapeutics (NASDAQ:CCCC) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Do institutionals & insiders have more ownership in CCCC or KLRS? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer CCCC or KLRS? C4 Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 206.51%. Kalaris Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 19.52%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe C4 Therapeutics is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CCCC or KLRS more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-325.88% -53.91% -33.26% Kalaris Therapeutics N/A -81.02%-65.15% Does the media prefer CCCC or KLRS? In the previous week, Kalaris Therapeutics had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for Kalaris Therapeutics and 0 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.00 beat Kalaris Therapeutics' score of -0.16 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Neutral Kalaris Therapeutics Neutral Which has more risk & volatility, CCCC or KLRS? C4 Therapeutics has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Which has higher valuation and earnings, CCCC or KLRS? Kalaris Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M5.22-$105.32M-$1.58-1.65Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A SummaryC4 Therapeutics beats Kalaris Therapeutics on 9 of the 13 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.94M$3.13B$5.83B$9.78BDividend YieldN/A2.24%4.40%4.05%P/E RatioN/A7.6222.8124.74Price / SalesN/A396.93473.17122.93Price / CashN/A44.5038.0259.36Price / Book0.888.129.536.60Net Income-$58.77M-$54.72M$3.26B$265.65M7 Day Performance2.03%2.62%2.14%2.02%1 Month Performance-9.39%2.68%2.81%-0.32%1 Year PerformanceN/A10.93%30.70%19.06% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics1.2835 of 5 stars$2.51+2.0%$3.00+19.5%N/A$46.94MN/A0.00110CCCCC4 Therapeutics1.2077 of 5 stars$2.46+4.7%$8.00+225.2%-56.9%$175.08M$34.24M-1.56150TVGNTevogen Bio3.9887 of 5 stars$0.95-3.2%$10.00+954.5%+55.8%$174.39MN/A0.003News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.8749 of 5 stars$1.63+5.2%$7.00+329.4%+45.8%$171.63MN/A-5.0910Positive NewsENTAEnanta Pharmaceuticals3.5238 of 5 stars$8.00+3.4%$21.67+170.8%-29.5%$171.02M$67.64M-1.85160LFVNLifevantage3.7028 of 5 stars$13.49-1.4%$30.50+126.1%+56.1%$169.81M$200.16M19.55260News CoveragePositive NewsUpcoming EarningsCYBNCybin2.4338 of 5 stars$7.06-1.5%$85.00+1,104.0%N/A$169.14MN/A-1.6150News CoverageAnalyst RevisionACTUActuate TherapeuticsN/A$8.12-1.2%$20.50+152.5%+3.9%$166.23MN/A0.0010News CoverageAnalyst DowngradeAnalyst RevisionGap DownNKTXNkarta2.0141 of 5 stars$2.33+5.9%$13.60+483.7%-54.0%$165.49MN/A-1.57140SLNSilence Therapeutics2.3938 of 5 stars$5.49-2.5%$33.83+516.3%-65.6%$164.17M$27.17M-3.33100NVCTNuvectis Pharma3.722 of 5 stars$6.43flat$15.33+138.5%-4.6%$163.69MN/A-5.508Positive News Related Companies and Tools Related Companies CCCC Competitors TVGN Competitors SLS Competitors ENTA Competitors LFVN Competitors CYBN Competitors ACTU Competitors NKTX Competitors SLN Competitors NVCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access